Option chain shows key data for Zelira Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Zelira Therapeutics.

Zelira Therapeutics (OTC:ZLDAF) Stock, Option Chain

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Biotech

Cannabis

News

Penny Stocks

Markets

General

ZLDAF

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a leading player in cannabinoid medicine research, has successfully demonstrated that its proprietary drug for diabetic nerve pain, ZLT-L-007, surpasses the efficacy of Pfizer Inc. (NYSE: 

This Cannabis-Based Drug Has Outperformed Pfizer&#39;s Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?

Photo: Courtesy of Rick Proctor On Unsplash

Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment

Small Cap

Management

AKAN

BHNGF

FREE

GNLN

HAIN

IXHL

KERN

STGW

TLLTF

TLRY

CSE:BHNG



Less than 30 years after Israel became the first nation in the world to allow its citizens to use cannabis for medical purposes, the medical and adult-use cannabis markets have spread across the globe at a dizzying rate.

A Global List Of Cannabis Operators And Executives To Keep An Eye On In 2022 And Beyond

ZELIRA THERAPEUTICS LTD by Zelira Therapeutics Ltd.

Zelira Therapeutics Ltd

Zelira Therapeutics

Comments

Zelira Therapeutics

Zelira Therapeutics (ZLDAF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell